Novonesis en las noticias
Soluciones biológicas para la sostenibilidad
Tamtam encontró 20 artículos recientes sobre Novonesis.
- Novonesis' bid for Microbiogen under review in Australia
- SEB raises Novonesis price target to 560 Danish kroner (545), reiterates buy
- Efficiency and sustainability go hand in hand in modern poultry production | Novonesis
- Novonesis raises 2026 outlook as first-half sales jump 8%
- Novonesis shares jump 9% after Q2 beat, raised 2026 sales guidance, buyback
- The science of HMOs – A novonesis webinar featuring new clinical findings and ESPGHAN highlights
- Novonesis Jumps as High-Protein Demand Helps Fuel Buyback
- Novonesis CEO: Earnings put us in a good place
- Novonesis Expects Results From Weight-Loss Drug Supplement Study in 2027
- Earnings call transcript: Novonesis raises 2026 outlook as shares jump 8.5%
- Morgan Stanley raises the price target for Novonesis to 535 Danish kroner (520), reiterates overweight - BN
- Novonesis expects results from weight-loss drug supplement study in 2027
- Novonesis Shares Jump as High Protein Demand Enables Buyback
- Novonesis Leads Europe’s Stoxx 600 on Sales Beat, Guidance Raise
- Novonesis H1 2026 Results: Organic sales up 8%, raises outlook
- Novonesis Approves EUR 1 Billion Share Buyback Program To Start In H2 2026
- Novonesis Says Outlook For FY Adjusted EBITDA Margin Is Now 37-38%
- DNB Carnegie raises the target price for Novonesis to 470 Danish kroner (450), reiterates buy
- H1 2026: Novonesis delivered strong 8% organic sales growth and increases full-year outlook
- Novonesis to roll out ₹3,000-crore Maharashtra investment over next 24-36 months
Artículos recopilados por Tamtam y conservados cuando tratan sobre la empresa, del más reciente al más antiguo. Cada uno enlaza con su fuente.
¿Vendes a empresas como Novonesis?
Tamtam encuentra las empresas que encajan con tu cliente ideal, investiga cada cuenta y te dice a quién contactar y cuándo.
Encontrar empresas similares